ALLCAR19: A phase 1 trial of CAR T-cell therapy in adults with relapsed or refractory DLBCL, CLL, SLL, FL or MCL

Trial aim and background

The aim of this trial is to find out whether the CAR T-cell therapy CD19-CAR-T is feasible and safe for people with diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL) or mantle cell lymphoma (MCL) who have relapsed after, or not responded (refractory) to, previous treatment.

Everybody who takes part in this trial has treatment with CAR T-cell therapy, if the cells can be made and grown successfully. People will have different dosing schedules depending on their underlying disease. After completing the treatment, all participants, regardless of whether they responded to treatment or not will enter a long term 10 year follow up phase

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

People aged over 16 with relapsed or refractory DLBCL, CLL/SLL, FL or MCL may be eligible for this study.

Locations

Recruitment is taking place at the University College London Hospital, London

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: clinicaltrials.gov/ct2/show/NCT02935257

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.